eCommons@AKU
Department of Paediatrics and Child Health

Division of Woman and Child Health

October 2015

Congenital factor VII deficiency in children at
tertiary health care facility in Pakistan
Muhammad Matloob Alam
Aga Khan University, matloob.alam@aku.edu

Bushra Moiz
Aga Khan University, bushra.moiz@aku.edu

Karim Abdur Rehman
Aga Khan University

Priyanka Jethwani
Aga Khan University

Zehra Fadoo
Aga Khan University, zehra.fadoo@aku.edu

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Pediatrics Commons
Recommended Citation
Alam, M. M., Moiz, B., Rehman, K. A., Jethwani, P., Fadoo, Z. (2015). Congenital factor VII deficiency in children at tertiary health
care facility in Pakistan. Clinical and Applied Thrombosis/Hemostasis, 21(7), 639-644.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/448

Original Article

Congenital Factor VII Deficiency in
Children at Tertiary Health Care
Facility in Pakistan

Clinical and Applied
Thrombosis/Hemostasis
2015, Vol. 21(7) 639-644
ª The Author(s) 2013
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1076029613515070
cath.sagepub.com

Muhammad Matloob Alam, MBBS, FCPS1,
Bushra Moiz, MBBS, FCPS2, Karim Abdur Rehman3,
Priyanka Jethwani3, and Zehra Fadoo, MBBS, MD1

Abstract
This study presents the demographics, clinical spectrum, and outcome of patients with congenital factor VII (FVII) deficiency at a
tertiary care center over a period of 12 years. Of the 49 patients, 27 (55%) patients were males. Consanguinity was found in 92%
of the patients. The median age of symptom onset was 2.4 (interquartile range [IQR]: 1.1-6.5) years with a median age of 5.8 (IQR:
3.1-10) years at diagnosis. Life-threatening complications like intracranial bleeding (ICB) and intra-abdominal bleeding (IAB) were
observed in 8 (16.4%) patients. We found that 11 (55%) of the 20 patients with FVII coagulant activity (FVIIc) <1% were either
asymptomatic or showed mild phenotype. In contrast, 9 (53%) of the 17 patients with FVIIc >5% were affected by severe symptoms. Age <1 year was the only identified risk factor associated with development of life-threatening bleeding episodes (P ¼ .042;
odds ratio 6.46). Overall, 4 (8.2%) died as a consequence of ICB (3 patients) and IAB (1 patient).
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Introduction
Congenital factor VII (FVII) deficiency (Online Mendelian
Inheritance in Man: 227500) is the commonest among the rare
congenital coagulation disorders and is characterized by autosomal recessive inheritance.1 Clinically symptomatic FVII
deficiency has an estimated prevalence of 1:500 000 without
any racial/ethnic predilection.2 However, true prevalence of
FVII deficiency is probably higher given the presence of
asymptomatic and mildly symptomatic individuals.3 A procoagulant, FVII, plays a pivotal role in the extrinsic coagulation
pathway. Its activated form VIIa combines with tissue factor,
released from damaged endothelial cells causing factor X activation which through a series of events leads to the formation
of a stable, fibrin clot. Additionally, FVII augments intrinsic
pathway by activating factor IX.4,5
Clinical heterogeneity is a feature of this hemorrhagic disorder concerning both sites and severity of bleeding that does not
always correlate with the level of FVII coagulant activity
(FVIIc) measured in plasma.6 A disease severity classification
has been formulated based on the timing and clinical presentation of the disease.3 The International Registry Factor Seven
Study Group (IRF7SG) classifies bleeding episodes as severe,
moderate, or mild (Table 1).7 Most severe cases of FVII deficiency are diagnosed during childhood, often during the first
6 months of life. In infancy, the gastrointestinal tract and

central nervous system (CNS) are the most common sites,
accounting for 60% to 70% of bleeds in this age group.8,9 In
mildly and moderately affected patients, symptoms are minimal and often restricted to post-traumatic/surgical
hemorrhage.3
The laboratory diagnosis of FVII deficiency is suggested by
a prolonged prothrombin time (PT) with a normal activated
partial thromboplastin time (aPTT) and confirmed based on a
low FVII assay. However, being a rare bleeding disorder, it
needs a high index of suspicion. Molecular diagnosis is available, and a broad spectrum of mutations has been characterized
in the FVII gene that is located on chromosome 13.4,5 Molecular analysis of a small series of 10 FVII-deficient patients found
5 novel mutations in Pakistan.10 This heterogeneity in the
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Table 1. The Clinical Severity Classification Recommended by the
IRF7SG.7
Severity
Classification
Severe
Moderate
Mild

Clinical Phenotype
CNS and/or GI bleed and/or hemarthrosis with or
without other bleeding symptoms
3 or more symptoms (except CNS and/or GI bleed
and/or hemarthrosis)
1 or 2 symptoms (except CNS bleed and/or GI
bleed and/or hemarthrosis)

Abbreviations: CNS, central nervous system; GI, gastrointestinal; IRF7SG,
International Registry Factor Seven Study Group.

genetic mutations may explain the broad spectrum of clinical
presentations seen to be associated with FVII deficiency.
A number of studies have been conducted in the past, with
data obtained from multiple centers and blood banks that provide a point prevalence of a number of inherited coagulation
disorders with common clinical presentations.1,2,11,12 However,
there have not been any studies focusing solely on the demographics, the implications of consanguineous marriages, clinical presentations, fatal complications, and long-term effects of
FVII deficiency in the population. The aim of this study was to
describe the baseline demographics, clinical spectrum, hemostatic values, and outcome of 49 pediatric patients who were
diagnosed with congenital FVII deficiency in a tertiary health
care facility of Karachi, Pakistan.

Methodology
This is a retrospective review of patients aged 0 to 18 years who
were diagnosed with FVII deficiency, at Aga Khan University
Hospital (AKUH), Karachi, over a period of 12 years from January 2001 to December 2012.

Data Collection
Admitted patients were identified using coded discharge
records with the diagnosis of coagulation/factor deficiency,
as there is no specific international classification of disease
(ICD) code available for FVII deficiency, ICDs (2008; code
286.3) were used for the identification of inpatient study populations. Outpatients were identified by outpatient department
record. Computerized laboratory system was utilized as an
additional source for identifying FVII-deficient patients. All
the FVII-deficient patients were diagnosed on the basis of having a minimum number of low FVII (<50%) levels. Patients’
medical charts were reviewed to evaluate nature of FVII deficiency—inherited or acquired. Patients with acquired FVII
deficiency secondary to liver disease, vitamin K deficiency,
or malabsorption were identified through prolonged PT and
aPTT as well as through multiple factor deficiencies and were
excluded from the study. These details were also verified
through laboratory information system using medical record
number for each patient.

Laboratory Workup
All tests were performed at the coagulation laboratory of The
Aga Khan University Hospital which is an ISO 9000 and Joint
Commission International-accredited laboratory. Besides stringent internal control, it regularly participates in external quality
assessment by College of American Pathologists.
Briefly, 1.8 mL of blood was collected in 3.2% sodium
citrate (BD, Becton Dickinson and Company, New Jersey).
Prothrombin time and aPTT were performed on Sysmex
CA-1500 system (Sysmex Corporation, Kobe, Japan) using
Dade, Innovin, and Actin FS reagents.13 The instrument and
reagents remained unchanged during the study period. Reference range established in our laboratory for FVII ranged from
50% to 150%. The diagnosis of FVII deficiency was typically
considered on the discordance between the PT and the normality of the aPTT. Factor VII assay was performed on the
same analyzer as described earlier utilizing clotting-based
methodology. All abnormal tests were repeated to confirm the
results, and the most recent level was used for stratification of
severity of FVII deficiency. Those having isolated FVII deficiency were evaluated for correction of PT with normal
plasma in a ratio of 1:1 (PT mixing test). The patients in
whom this could not be achieved were considered to have
acquired autoimmune FVII deficiency and were also excluded
from the study.

Data Handling
Data were collected on a prestructured proforma by reviewing
medical records and phone interviews that were done to complete the missing data by primary investigator. Information
including gender, age at presentation and at the time of diagnosis, presenting complaints, family history, consanguinity,
applied treatment, surgical interventions, complications, and
follow-up visits were recorded. The patients were also evaluated for type, site, frequency, nature, and severity of bleeding
manifestations. Hemoglobin level, platelet count, peripheral
smear, and result of coagulation screen (PT, aPTT, and BT)
were also recorded. Patients were grouped according to clinical
severity classification (Table 1) as recommended by the
IRF7SG5 and FVIIc level for further analysis.

Statistical Analysis
For data entry and analysis, SPSS version 20.0 (IBM, Chicago)
was used. Median with interquartile range (IQR) of age and
mean with standard deviation of FVII levels was computed,
while frequency (percentage) for gender, consanguinity in parents, family history of bleeding disorder/FVII deficiency, and
complications were calculated. Regression analysis was performed for the identification of risk factors for lifethreatening bleeding episodes, and crude odd ratio (OR) was
calculated. A P value of <.05 was considered significant at the
univariate level.
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Table 2. Demographic Parameters of Factor VII-Deficient Patients.

Gender
Male
Female
Age at symptom onset 2.4 (IQR: 1.1-6.5) years
<1 year
2-5 years
5-10 years
>10 years
Age at diagnosis 5.8 (IQR: 3.1-10) years
Lab diagnosis within 6 month of symptom onset
Factor VII coagulation activity
<1%
1-5%
>5%
Clinical severity classification
Mild
Moderate
Severe
Family history
Positive
Consanguineous marriage

30

Number (%)
27 (55)
22 (45)
19
8
12
10

(39)
(16)
(24)
(20)

25
No of paents

Characteristics

20
15
10
5
0

13/42 (31)
20 (41)
12 (24)
17 (35)
16 (33)
14 (28)
19 (39)
12 (25)
45 (92)

Abbreviation: IQR, interquartile range.

Ethical Approval
The study was approved by the Ethical Review Board (ERB) of
Aga Khan University, Karachi (2396-Ped-ERC-12).

Results
Demographics
A total of 49 FVII-deficient patients were identified during the
study period. Table 2 describes the demographic features of all
enrolled patients. There were 27 (55%) males and 22 (45%)
females. The rate of consanguinity among the parents of
patients was 92%. In all, 5 patients had bleeding disorder in
their siblings, while significant family history of bleeding was
observed in 7 patients.

Clinical Manifestations of FVII deficient patients

Figure 1. The bleeding sites and frequency of bleeding episodes of
symptomatic patients. ICB indicates intracranial bleed; GI, gastrointestinal; UCB, umbilical cord bleed; PC bleed, post-circumcision bleed.
*Sex adjusted frequency for PC bleed is 22% (6 of 22). **Age and
gender adjusted frequency for menorrhagia is 45% (5 of 11).

Symptomatology
The bleeding sites and frequency of bleeding episodes are
shown in Figure 1. The most common symptoms were epistaxis, easy bruisability, prolonged umbilical cord and postcircumcision bleeding, gastrointestinal (GI) bleeding, and
gum bleeding. Intracranial bleeding (ICB) and intraabdominal bleeding (IAB) were among the life-threatening
events and were observed in 8 (16.4%) patients. Comparison
of the mean age at presentation for specific symptoms yielded
a significant difference. In particular, of the 8 patients who
presented with life-threatening bleeding, 6 (75%) of them presented within the first year of life. In our study, all the bleeding episodes were treated with fresh frozen plasma (FFP)
transfusions. Additionally, in 3 cases of impending lifethreatening bleeding recombinant-activated FVII (rFVIIa
70-90 mg/kg) was given before surgery. All patients were then
kept on regular FFP transfusion until the hemostasis was
achieved.

Severity, FVII level, and Complications
Age of Onset and at Diagnosis
The median age of symptom onset of this cohort was 2.4 (IQR:
1.1-6.5) years and median age at the time of diagnosis was 5.8
(IQR: 3.1-10) years. Age at symptom onset was compared with
age at laboratory diagnosis in the 42 patients for whom both
time points were available. In only 31% (13 of 42) of the
patients, diagnosis of FVII deficiency was made simultaneously or within 6 months of symptom onset. There was considerable delay in establishing laboratory diagnosis in the
remaining patients, median age at diagnosis of this cohort (29
of 42) was 6.9 (IQR: 4.1-11) years, and mean time lag before
laboratory diagnosis was 4.3 (IQR: 1.8-9.5) years.

According to clinical severity classification, 16 (33%), 14
(28%), and 19 (39%) patients had mild, moderate, and severe
phenotype, respectively. The levels of FVIIc were as follows:
20 (41%) patients; <1%, 12 (24%) patients; 1% to 5%, and
17 (35%) patients; >5% to 50%. We found that 11 (55%) of the
20 patients with FVIIc level less than 1% were either asymptomatic or showed a very mild phenotype. In contrast, 9 (53%) of
the 17 patients with FVIIc level above 5% were affected by
severe symptoms (GI in 4 patients, CNS in 3 patients, and
hemarthrosis in 2 patients). A total of 8 patients had lifethreatening bleeding episodes (7 ICB and 1 IAB bleedings),
4 of whom died as a consequence of bleeding.
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Table 3. Comparison of Factor VII-Deficient Patient With and Without Life-Threatening Bleeding Episodes.
Total Number (n ¼ 49)
Life-Threatening Bleeding
Variables

Present, n ¼ 8 (%)

Gender
Male
5 (63)
Family history of bleeding
3 (38)
Consanguinity in parents
7 (88)
Age at symptom onset
< 1 year
6 (75)
> 1 year
2 (25)
Age at lab diagnosis
< 1 year
3 (37)
>1 year
5 (63)
Lab diagnosis within 6 month of symptom onset
3 (37)
Factor VII level (%)
< 5%
6 (75)
> 5%
2 (25)
Clinical severity classification before life-threatening bleeding episodes
Mild to moderate
6 (75)
Severe
2 (25)
Outcome expired
4 (50)

Absent, n ¼ 41 (%)

P Value

Crude OR (CI)

22 (54)
9 (23)
38 (93)

0.943
0.627
0.829

1.44 (0.31-6.83)
2.13 (0.47-10.68)
0.55 (0.05-6.11)

13 (32)
28 (68)

0.042

6.46 (1.15-36.46)

5 (12)
36 (88)
10 (24)

0.212

4.32 (0.78-23.88)

0.741

1.86 (0.38-9.21)

26 (63)
15 (37)

0.823

1.73 (0.31-9.68)

24 (58)
17 (42)
0 (0)

0.562

2.32 (0.42-12.96)

–

–

Abbreviations: CI, confidence interval; Lab, laboratory; OR, odds ratio.

Outcomes
Of the 4 (8.2%) mortalities, 3 patients died due to ICB and 1 due
to IAB. Age less than 1 year (P ¼ .042; crude OR 6.46) was the
only identified risk factor associated with the development of
life-threatening bleeding episodes on regression analysis that
compared the FVII-deficient patient with and without lifethreatening bleeding episodes (Table 3). Of the 45 alive patients,
22 patients have no further bleeding complaints, 15 have on and
off minor, self-resolving bleeding episodes, and 9 patients are on
regular monthly prophylactic FFP transfusions and doing well
with no major bleeding episodes per telephonic interviews. The
rationale behind the monthly FFP transfusions could not be
ascertained as the interviews were with the patient’s families and
not the treating physicians. Outcome data for the remaining 3
patients were missing because they lost to follow-up.

Discussion
Many centers and study groups are evaluating data for rare congenital factor deficiencies for a better understanding of their
genetic characteristics, clinical presentations, and developing
treatment protocols since the 2000s.11,12 The World Federation
of Hemophilia and Rare Bleeding Disorders Database are
among some examples of such initiative.14 Others include the
International Registry on Congenital Factor VII deficiency and
the Seven Treatment Evaluation Registry.
Our single-center study group comprised 49 pediatric
patients diagnosed with FVII deficiency over a period of 12
years with a median age of 5.8 (IQR: 3.1-10) years at diagnosis.
The minimum age of presentation ranged from 0 years to a

maximum age of 18. Although this congenital deficiency is rare
globally, our single study experience revealed a large number
of FVII-deficient patients that can be attributed to a high frequency of consanguineous marriages in the region and to the
autosomal recessive pattern of inheritance of the disease. As
with most autosomal recessive disorders, incidence of congenital FVII deficiency is directly associated with consanguinity in
parents. Hussain and Bittles reported that approximately 60%
of all Pakistani marriages were consanguineous and 80% of
these are between first cousins.15 Therefore, diseases with
familial tendencies may be associated with higher prevalence
in Pakistan than in other countries.
Literature review revealed a wide age distribution for diagnosis among registered FVII-deficient patients by different
group. The IRF7SG study reported an age distribution range
of 1 to 90 years,7 and the mean age of 30 years was reported
by Herrmann et al.16
Studies report that the most common bleeding sites are skin
and mucosal tissue,6,12 most commonly, for example, epistaxis,
menorrhagia, gum bleeding, and easy bruising. In our study,
prolonged umbilical cord bleeding 32.7% (16 of 49), bruising
30.6% (15 of 49), and epistaxis 26.5% (13/49) were the 3 most
common presenting complaints of patients with mild to moderate bleeding. Hemorrhage involving the CNS was seen in
14.3% (7 of 49) of the patients, a figure that matched findings
of 16% (12 of 75) and 17% reported by Ragni et al17 and Peyvandi et al,12 respectively, whereas the IRF7SG study and Salcioglu et al18 reported the frequency of CNS bleeding as 7%
and 19% (8 of 42), respectively.
Intracranial bleeding is known to be a life-threatening complication and a significant risk of early mortality in deficient
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individuals.19 This was reiterated by our study, in which 3
(6.1%) study participants died due to ICB. Hemarthrosis was
a less common presentation in our study (6%) as opposed to
other literature, which showed a bleeding frequency of 16.6%
to 22%.3,12 Children less than 5 years were most commonly
affected, especially as this is the time when they start to crawl
and walk.20 The frequency of gastrointestinal bleedings, 14.3%
in our study, was comparable with figures of 14% reported by
Peyvandi, Lapecorella, and IRF7SG.
Many studies report menorrhagia as a presenting complaint
in females with FVII deficiency. Prevalence is shown to be as
high as 60%.21,22 The frequency of menorrhagia in FVIIdeficient individuals is in accordance with the findings in other
bleeding disorders like von Willebrand disease.8 Our study,
however, only indicates 10% prevalence of menorrhagia in
girls with FVII deficiency. This discrepancy is most likely due
to the fact that majority female participants in our study were of
a younger age group and had not attained menarche yet. In our
study, however, age and sex-adjusted frequency for menorrhagia was 45% (5 of 11).
Bleeding in the severest of cases occurs in the first 6 months
of life, but it is not uncommon to observe spontaneous bleeding
and bleeding after provocation, such as during and after surgery
in older age groups. One study showed that as high as 76% of
FVII-deficient patients were diagnosed in their first year of
life.18 It has also been seen that infants and neonates with
low-FVII levels carry a heavy bleeding risk.5
Also, it was seen that there was a delay in diagnosis of the
deficiency. Our study showed that the mean age of symptom
onset was seen to be significantly different from the age of
diagnosis. This observation could be explained by the fact that
patients are often treated with packed red cells and various
other forms of blood products that tend to mask the underlying
coagulopathy. The need for diagnostic investigations instead of
just symptomatic treatment is highlighted by this finding.
It is not rare to see a lack of bleeding complications, either
spontaneous or provoked, in those with circulating functional
factor levels of less than 1%.23-25 On the other hand, there have
been reports of severe bleeding in patients with factor levels of
more than 5%.26 Likewise, our study shows that 55% of the
patients with FVIIc <1% were either asymptomatic or mildly
symptomatic, whereas 53% patients with FVIIc >5% were
affected by severe symptoms involving the GI system, CNS,
and joints.
The life-threatening nature of FVII deficiency also came to
light in our study. There were 4 (8.2%) deaths, 3 of which was a
result of ICB and 1 of which was secondary to an IAB. Intracranial bleeding and IAB are serious complications and other
studies also identify them as significant contributors to morbidity.2 Studies on boys with hemophilia show that intracranial
hemorrhages, even when adequately treated, have poor longterm outcomes, especially in the domain of quality of life.27
As with other factor deficiencies, substitutional therapy is the
main stay of treatment in FVII-deficient individuals with a history of bleeding. Asymptomatic patients undergoing minor surgical procedures can be successfully treated with Tranexamic
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acid. Prophylaxis is not a common practice; however, reports
suggest that prophylaxis may be beneficial in unweaned infants,
menorrhagia with iron deficiency, and recurrent haemarthrosis.28,29 Moreover, continuous infusion of rFVIIa in surgical procedures has also been reported. Complications of treatment are
rare and include transmission of blood-borne viruses, thrombosis, and inhibitors to FVII.30
Limitations of this study include those inherent to its single
center, retrospective design particularly selection bias and
information bias. Additionally, we do not have the facilities for
detection of specific mutations in these patients, and relationship between genotype and phenotype remains to be investigated in future.

Conclusions
Clinical manifestations are variable and do not necessarily correlate with factor levels but its deficiency is associated with
severe bleeding and death, particularly in the infant and neonatal proportion of the pediatric population. Therefore, it is
important for neonatologists and pediatricians to investigate
bleeding diathesis in this age group thoroughly. With a high
rate of consanguinity and subsequently higher rate of coagulation deficiencies in the region, large-scale multicenter studies
are warranted to assess the magnanimity of the situation.
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